- Home
- ECO vs FLGT Comparison
ECO vs FLGT Comparison
Compare ECO & FLGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ECO | FLGT |
|---|---|---|
| Founded | 2018 | 2011 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | | Medical Specialities |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 867.4M |
| IPO Year | N/A | 2016 |
Fundamental Metrics
Financial Performance| Metric | ECO | FLGT |
|---|---|---|
| Price | $32.75 | $27.07 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 3 |
| Target Price | ★ $37.00 | $28.33 |
| AVG Volume (30 Days) | ★ 268.3K | 220.2K |
| Earning Date | 11-12-2025 | 11-07-2025 |
| Dividend Yield | ★ 6.50% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.38 | N/A |
| Revenue | ★ $349,886,578.00 | $315,549,000.00 |
| Revenue This Year | N/A | $16.84 |
| Revenue Next Year | $3.29 | $9.74 |
| P/E Ratio | $13.69 | ★ N/A |
| Revenue Growth | N/A | ★ 13.61 |
| 52 Week Low | $17.91 | $14.57 |
| 52 Week High | $39.77 | $31.04 |
Technical Indicators
Market Signals| Indicator | ECO | FLGT |
|---|---|---|
| Relative Strength Index (RSI) | 33.14 | 45.66 |
| Support Level | $31.82 | $26.63 |
| Resistance Level | $34.06 | $28.26 |
| Average True Range (ATR) | 0.83 | 0.66 |
| MACD | -0.51 | -0.20 |
| Stochastic Oscillator | 14.65 | 19.79 |
Price Performance
Historical ComparisonAbout ECO Okeanis Eco Tankers Corp.
Okeanis Eco Tankers Corp owns and operates tanker vessels in Greece. The business of the company is to own, charter out, and operate tanker vessels. The company owns, through its vessel-owning subsidiaries, a fleet of around seven tanker vessels and has around eight tanker vessels on order. The sailing fleet consists of around six modern Suezmax tankers and eight VLCC tankers.
About FLGT Fulgent Genetics Inc.
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in laboratory services business and a therapeutic development business. The laboratory services business which generates key revenue includes, technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign.